stockrow
Monday 9 November 2026
Export BCYC’s income statement to Excel — free account
Bicycle Therapeutics PLC Sponsored ADR
BCYCBicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.
- Revenue
- +190.2%
- EPS
- +82.4%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
3.61
0.13
+3.74%
Follow BCYC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.76 | 5.09 | 4.84 | 3.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(25.35) | (4.90) | (5.97) | (6.39) | |
P/B ratio |
0.80 | 0.58 | 0.58 | 0.51 | |
Price to Tangible BV |
0.80 | 0.58 | 0.58 | 0.51 | |
EV/Sales |
(1.61) | (3.39) | (3.15) | (2.29) | |
EV/EBITDA |
0.48 | 0.91 | 0.94 | 1.25 | |
EV/Operating CF |
0.47 | 0.94 | 0.94 | 1.09 | |
EV/FCF |
0.46 | 0.93 | 0.93 | 1.08 | |
Quick Ratio |
11.65 | 12.28 | 11.70 | 11.75 | |
Current Ratio |
11.98 | 12.66 | 12.08 | 12.09 | |
Net Debt/EBITDA |
26.87 | 8.69 | 9.54 | 37.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.08 | 0.09 | 0.13 | |
Operating CF/Net income |
0.96 | 1.08 | 0.99 | 3.85 | |
Capex/Depreciation |
(0.43) | (0.63) | (0.25) | (0.28) | |
Interest Coverage |
(433.47) | (1,364.21) | (1,239.98) | (299.49) | |
Research and Development Expense of Revenue |
107.96% | 5,513.08% | 6,543.72% | 98.14% | |
Selling, General and Administrative Expense of Revenue |
43.57% | 1,969.33% | 2,230.21% | 41.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
24.30% | 781.29% | 1,018.12% | 15.91% | |
Graham Net Nets |
1.17 | 1.61 | 1.62 | 1.85 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(44.63%) | (67.89%) | (64.39%) | (55.15%) | |
Free Cash Flow Yield |
(51.38%) | (71.66%) | (70.37%) | (68.74%) | |
Revenue per Share |
0.69 | 0.01 | 0.01 | 0.49 | |
Operating CF per Share |
(0.28) | (0.95) | (0.71) | (0.58) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.29) | (0.96) | (0.71) | (0.58) | |
Cash per Share |
9.07 | 8.03 | 7.31 | 6.72 | |
Shareholders Equity per Share |
8.80 | 7.95 | 7.31 | 7.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.80 | 7.95 | 7.31 | 7.22 | |
Free Cash Flow |
(19.92) | (66.64) | (49.87) | (40.61) | |
Working Capital |
625.90 | 570.25 | 527.60 | 493.10 | |
Capital Expenditures |
(0.57) | (0.71) | (0.26) | (0.30) | |
Net Current Asset Value |
575.27 | 521.06 | 478.91 | 475.65 | |
EV/EBIT |
0.47 | 0.89 | 0.92 | 1.21 | |
Capex to Sales |
0.01 | 0.80 | 0.42 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
35.62 | 43.65 | 54.09 | 59.81 | |
Average Payables |
12.73 | 8.54 | 11.96 | 11.12 | |
Average Assets |
837.23 | 768.15 | 719.38 | 665.57 | |
Average Common Equity |
701.52 | 647.33 | 589.59 | 561.88 |
Columns are period end dates · fundamentals updated 2 Nov 2026